NCT07527325 2026-04-14
Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma
University of California, Irvine
Phase 2 Not yet recruiting
Clinical Trials
25 trialsNCT07517653 2026-04-08
Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07513454 2026-04-07
A Phase 2 Study of HW211026 in Participants With Actinic Keratosis
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase 2 Not yet recruiting
NCT07511036 2026-04-06
PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07501104 2026-03-30
TRIUMPH-AM
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT07492121 2026-03-25
GAPIMET
University of Zurich
Phase 2 Not yet recruiting
NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT06708455 2026-03-19
Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma
Rapa Therapeutics LLC
Phase 2 Not yet recruiting
NCT07227350 2026-03-10
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Philogen S.p.A.
Phase 2 Not yet recruiting
NCT07227870 2026-03-09
L19IL2/TNF in Patients With Basal Cell Carcinoma
Philogen S.p.A.
Phase 2 Not yet recruiting
NCT07455331 2026-03-06
LANCE
Jules Bordet Institute
Phase 2 Not yet recruiting
NCT07405086 2026-02-12
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT07406724 2026-02-12
HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 2 Not yet recruiting
NCT07387198 2026-02-04
NeoMatryx
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Not yet recruiting
NCT07340619 2026-01-14
EPIBREAST
UNICANCER
Phase 2 Not yet recruiting
NCT07040280 2025-06-27
Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Patients With a Prior History of Melanoma
Eastern Cooperative Oncology Group
Phase 2 Not yet recruiting
NCT06976021 2025-05-16
INTROSPECTION
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Not yet recruiting
NCT04429308 2025-05-08
PDT vs Peels for Treatment of Actinic Keratoses
Northwestern University
Phase 2 Not yet recruiting
NCT06670300 2024-11-01
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06500091 2024-07-15
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Not yet recruiting
NCT06470880 2024-06-24
DyNAMIc
The Christie NHS Foundation Trust
Phase 2 Not yet recruiting
NCT06327698 2024-03-25
Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure
Hunan Cancer Hospital
Phase 2 Not yet recruiting
NCT06183736 2023-12-27
CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
Convalife (Shanghai) Co., Ltd.
Phase 2 Not yet recruiting
NCT06086288 2023-10-17
PANDORA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Not yet recruiting
NCT02498756 2015-07-15
Cytokine-induced Killer Study for Patients With Stage II Melanoma
The First People's Hospital of Changzhou
Phase 2 Not yet recruiting